Aspirin-triggered proresolving mediators stimulate resolution in cancer

Area of Science:

• Oncology
• Inflammation Biology
• Pharmacology

Background:

• Tumor microenvironment inflammation promotes cancer growth.
• Aspirin reduces cancer risk, but mechanisms and toxicity are concerns.
• Aspirin triggers anti-inflammatory mediators like aspirin-triggered specialized proresolving mediators (AT-SPMs).

Purpose of the Study:

• To elucidate the mechanism of aspirin's anticancer effects.
• To investigate the role of AT-SPMs in mediating aspirin's antitumor activity.
• To explore AT-SPMs as a potentially less toxic cancer treatment approach.

Main Methods:

• Genetic and pharmacologic manipulation of proresolving receptors in mouse models.
• Treatment of mice with specific AT-SPMs (AT-RvDs, AT-LXA4).
• Assessment of primary tumor growth, macrophage phagocytosis, and cytokine profiles.

Main Results:

• Aspirin-triggered resolvins (AT-RvDs) were shown to mediate aspirin's antitumor effects.
• AT-SPM treatment inhibited tumor growth in mice.
• AT-SPMs enhanced macrophage phagocytosis and reduced pro-inflammatory cytokines.

Conclusions:

• The pro-resolution activity of AT-SPMs contributes to aspirin's anticancer effects.
• AT-SPMs may offer a less toxic alternative for cancer therapy.
• Targeting AT-SPM pathways could harness aspirin's cancer-fighting properties.